Drugs for Vulvovaginal Candidiasis Market By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others) , By Route of Administration (Oral, Intravenous, Topical) By Distribution Channel (Hospital Pharmacy, Retail Ph
Description
Drugs for Vulvovaginal Candidiasis Market By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others) , By Route of Administration (Oral, Intravenous, Topical) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The drugs for vulvovaginal candidiasis market was valued at $1.0 billion in 2023, and is projected to reach $1.6 billion by 2033, growing at a CAGR of 4.4% from 2024 to 2033.
Drugs for vulvovaginal candidiasis are pharmaceutical agents used to treat fungal infections caused by the overgrowth of Candida species in the vaginal and vulvar regions. These drugs aim to alleviate symptoms such as itching, discharge, and inflammation while eradicating the underlying fungal pathogen. Treatment options include topical antifungals (creams and suppositories) and systemic medications (oral antifungals), with varying durations depending on the severity of the infection.
The global drugs for vulvovaginal candidiasis market is witnessing robust growth due to alarming rise in the prevalence of vulvovaginal candidiasis due to factors such as higher rates of diabetes, hormonal fluctuations, and antibiotic use. Studies reveal that vulvovaginal candidiasis is the second most common infection prevalent among women worldwide. According to a study conducted by the National Institutes of Health—one of the world's foremost medical research centers—75% of women experience at least one episode of vulvovaginal candidiasis during their lifetime. This highlights the increasing need for therapeutic drugs for effective treatment. Furthermore, increase in awareness campaigns and educational efforts regarding vaginal health have led to earlier diagnosis and treatment-seeking behavior, thereby propelling the market for r vulvovaginal candidiasis drugs. Moreover, rise in access to over-the-counter antifungals has made treatment accessible to a larger population, particularly in developed regions, which notably contributes toward the market growth. Factors such as sedentary lifestyles, poor hygiene, and the growing use of hormonal contraceptives have further contributed to a higher incidence of vulvovaginal candidiasis, supporting the demand for therapeutic drugs. In addition, availability of treatments through online pharmacies and telemedicine platforms has made it easier for patients to access medications, which is expected to foster the market growth. However, emergence of drug-resistant Candida strains, particularly Candida glabrata and Candida krusei, has reduced the efficacy of commonly used antifungal agents, such as azoles, limiting treatment options. In addition, adverse effects like gastrointestinal discomfort, liver toxicity, and allergic reactions discourage the use of certain systemic antifungal drugs, thus hampering the market growth. On the contrary, the introduction of single-dose oral treatments like fluconazole and innovative formulations such as extended-release suppositories or vaginal tablets has enhanced patient compliance. Such developments are expected to offer remunerative opportunities for the expansion of the global market during the forecast period.
The global drugs for vulvovaginal candidiasis market is segmented into drug class, route of administration, distribution channel, and region. On the basis of the drug class, the market is categorized into clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. By route of administration, it is classified into oral, intravenous, and topical. Depending on distribution channel, it is divided into hospital pharmacy, retail pharmacy, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By drug class, the fluconazole segment is expected to dominate the market from 2024 to 2033.
On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the retail pharmacy segment is projected to grow at a notable pace in the coming years.
Region wise, North America emerged as the most lucrative market for vulvovaginal candidiasis drugs; however, Asia-Pacific is likely to register the highest growth throughout the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global drugs for vulvovaginal candidiasis market include Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Bayer AG, Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc., Zydus Lifesciences Ltd., Bristol-Myers Squibb Company, and Amneal Pharmaceuticals LLC. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market Segments
By Drug Class
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route Of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Astellas Pharma Inc
Mycovia Pharmaceuticals, Inc.
Bayer AG
Basilea Pharmaceutica Ltd
Scynexis, Inc.
Grupo Ferrer Internacional S.A.
Pfizer, Inc.
Zydus Lifesciences Ltd.
Bristol-Myers Squibb Company
Amneal Pharmaceuticals LLC
Table of Contents
240 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Class
- 4.2. Clotrimazole
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Nystatin
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Fluconazole
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Ketoconazole
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Terbinafine
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- 4.7. Terconazole
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country
- 4.8. Others
- 4.8.1. Key Market Trends, Growth Factors and Opportunities
- 4.8.2. Market Size and Forecast, By Region
- 4.8.3. Market Share Analysis, By Country
- CHAPTER 5: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Route Of Administration
- 5.2. Oral
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Intravenous
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Topical
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- CHAPTER 6: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacy
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacy
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Providers
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug Class
- 7.2.3. Market Size and Forecast, By Route Of Administration
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Drugs for Vulvovaginal Candidiasis Market
- 7.2.6.1. Market Size and Forecast, By Drug Class
- 7.2.6.2. Market Size and Forecast, By Route Of Administration
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Drugs for Vulvovaginal Candidiasis Market
- 7.2.7.1. Market Size and Forecast, By Drug Class
- 7.2.7.2. Market Size and Forecast, By Route Of Administration
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Drugs for Vulvovaginal Candidiasis Market
- 7.2.8.1. Market Size and Forecast, By Drug Class
- 7.2.8.2. Market Size and Forecast, By Route Of Administration
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug Class
- 7.3.3. Market Size and Forecast, By Route Of Administration
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Drugs for Vulvovaginal Candidiasis Market
- 7.3.6.1. Market Size and Forecast, By Drug Class
- 7.3.6.2. Market Size and Forecast, By Route Of Administration
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. France Drugs for Vulvovaginal Candidiasis Market
- 7.3.7.1. Market Size and Forecast, By Drug Class
- 7.3.7.2. Market Size and Forecast, By Route Of Administration
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. UK Drugs for Vulvovaginal Candidiasis Market
- 7.3.8.1. Market Size and Forecast, By Drug Class
- 7.3.8.2. Market Size and Forecast, By Route Of Administration
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Italy Drugs for Vulvovaginal Candidiasis Market
- 7.3.9.1. Market Size and Forecast, By Drug Class
- 7.3.9.2. Market Size and Forecast, By Route Of Administration
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. Spain Drugs for Vulvovaginal Candidiasis Market
- 7.3.10.1. Market Size and Forecast, By Drug Class
- 7.3.10.2. Market Size and Forecast, By Route Of Administration
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Drugs for Vulvovaginal Candidiasis Market
- 7.3.11.1. Market Size and Forecast, By Drug Class
- 7.3.11.2. Market Size and Forecast, By Route Of Administration
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug Class
- 7.4.3. Market Size and Forecast, By Route Of Administration
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Drugs for Vulvovaginal Candidiasis Market
- 7.4.6.1. Market Size and Forecast, By Drug Class
- 7.4.6.2. Market Size and Forecast, By Route Of Administration
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. China Drugs for Vulvovaginal Candidiasis Market
- 7.4.7.1. Market Size and Forecast, By Drug Class
- 7.4.7.2. Market Size and Forecast, By Route Of Administration
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Drugs for Vulvovaginal Candidiasis Market
- 7.4.8.1. Market Size and Forecast, By Drug Class
- 7.4.8.2. Market Size and Forecast, By Route Of Administration
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. Australia Drugs for Vulvovaginal Candidiasis Market
- 7.4.9.1. Market Size and Forecast, By Drug Class
- 7.4.9.2. Market Size and Forecast, By Route Of Administration
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. South Korea Drugs for Vulvovaginal Candidiasis Market
- 7.4.10.1. Market Size and Forecast, By Drug Class
- 7.4.10.2. Market Size and Forecast, By Route Of Administration
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Market
- 7.4.11.1. Market Size and Forecast, By Drug Class
- 7.4.11.2. Market Size and Forecast, By Route Of Administration
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug Class
- 7.5.3. Market Size and Forecast, By Route Of Administration
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Drugs for Vulvovaginal Candidiasis Market
- 7.5.6.1. Market Size and Forecast, By Drug Class
- 7.5.6.2. Market Size and Forecast, By Route Of Administration
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Drugs for Vulvovaginal Candidiasis Market
- 7.5.7.1. Market Size and Forecast, By Drug Class
- 7.5.7.2. Market Size and Forecast, By Route Of Administration
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Drugs for Vulvovaginal Candidiasis Market
- 7.5.8.1. Market Size and Forecast, By Drug Class
- 7.5.8.2. Market Size and Forecast, By Route Of Administration
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Drugs for Vulvovaginal Candidiasis Market
- 7.5.9.1. Market Size and Forecast, By Drug Class
- 7.5.9.2. Market Size and Forecast, By Route Of Administration
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Astellas Pharma Inc
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Mycovia Pharmaceuticals, Inc.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Bayer AG
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Basilea Pharmaceutica Ltd
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Scynexis, Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Grupo Ferrer Internacional S.A.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Pfizer, Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Zydus Lifesciences Ltd.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Bristol-Myers Squibb Company
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Amneal Pharmaceuticals LLC
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 2. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR CLOTRIMAZOLE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR NYSTATIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR FLUCONAZOLE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR KETOCONAZOLE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR TERBINAFINE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR TERCONAZOLE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 10. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR ORAL, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR INTRAVENOUS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR TOPICAL, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 14. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 15. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR RETAIL PHARMACY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 17. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 18. NORTH AMERICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 19. NORTH AMERICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 20. NORTH AMERICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 21. NORTH AMERICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 22. U.S. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 23. U.S. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 24. U.S. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 25. CANADA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 26. CANADA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 27. CANADA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 28. MEXICO DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 29. MEXICO DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 30. MEXICO DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 31. EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 32. EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 33. EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 34. EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 35. GERMANY DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 36. GERMANY DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 37. GERMANY DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 38. FRANCE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 39. FRANCE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 40. FRANCE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 41. UK DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 42. UK DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 43. UK DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 44. ITALY DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 45. ITALY DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 46. ITALY DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 47. SPAIN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 48. SPAIN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 49. SPAIN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 50. REST OF EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 51. REST OF EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 52. REST OF EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 53. ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 54. ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 55. ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 56. ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 57. JAPAN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 58. JAPAN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 59. JAPAN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 60. CHINA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 61. CHINA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 62. CHINA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 63. INDIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 64. INDIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 65. INDIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 66. AUSTRALIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 67. AUSTRALIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 68. AUSTRALIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 69. SOUTH KOREA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 70. SOUTH KOREA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 71. SOUTH KOREA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 72. REST OF ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 73. REST OF ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 74. REST OF ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 75. LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 76. LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 77. LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 78. LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 79. BRAZIL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 80. BRAZIL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 81. BRAZIL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 82. SAUDI ARABIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 83. SAUDI ARABIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 84. SAUDI ARABIA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 85. SOUTH AFRICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 86. SOUTH AFRICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 87. SOUTH AFRICA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 88. REST OF LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 89. REST OF LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 90. REST OF LAMEA DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, BY DISTRIBUTION CHANNEL , 2024 - 2033 ($BILLION)
- TABLE 91. ASTELLAS PHARMA INC: KEY EXECUTIVES
- TABLE 92. ASTELLAS PHARMA INC: COMPANY SNAPSHOT
- TABLE 93. ASTELLAS PHARMA INC: OPERATING SEGMENTS
- TABLE 94. ASTELLAS PHARMA INC: PRODUCT PORTFOLIO
- TABLE 95. ASTELLAS PHARMA INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96. MYCOVIA PHARMACEUTICALS, INC.: KEY EXECUTIVES
- TABLE 97. MYCOVIA PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 98. MYCOVIA PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 99. MYCOVIA PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 100. MYCOVIA PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101. BAYER AG: KEY EXECUTIVES
- TABLE 102. BAYER AG: COMPANY SNAPSHOT
- TABLE 103. BAYER AG: OPERATING SEGMENTS
- TABLE 104. BAYER AG: PRODUCT PORTFOLIO
- TABLE 105. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 106. BASILEA PHARMACEUTICA LTD: KEY EXECUTIVES
- TABLE 107. BASILEA PHARMACEUTICA LTD: COMPANY SNAPSHOT
- TABLE 108. BASILEA PHARMACEUTICA LTD: OPERATING SEGMENTS
- TABLE 109. BASILEA PHARMACEUTICA LTD: PRODUCT PORTFOLIO
- TABLE 110. BASILEA PHARMACEUTICA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111. SCYNEXIS, INC.: KEY EXECUTIVES
- TABLE 112. SCYNEXIS, INC.: COMPANY SNAPSHOT
- TABLE 113. SCYNEXIS, INC.: OPERATING SEGMENTS
- TABLE 114. SCYNEXIS, INC.: PRODUCT PORTFOLIO
- TABLE 115. SCYNEXIS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 116. GRUPO FERRER INTERNACIONAL S.A.: KEY EXECUTIVES
- TABLE 117. GRUPO FERRER INTERNACIONAL S.A.: COMPANY SNAPSHOT
- TABLE 118. GRUPO FERRER INTERNACIONAL S.A.: OPERATING SEGMENTS
- TABLE 119. GRUPO FERRER INTERNACIONAL S.A.: PRODUCT PORTFOLIO
- TABLE 120. GRUPO FERRER INTERNACIONAL S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 121. PFIZER, INC.: KEY EXECUTIVES
- TABLE 122. PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 123. PFIZER, INC.: OPERATING SEGMENTS
- TABLE 124. PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 125. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 126. ZYDUS LIFESCIENCES LTD.: KEY EXECUTIVES
- TABLE 127. ZYDUS LIFESCIENCES LTD.: COMPANY SNAPSHOT
- TABLE 128. ZYDUS LIFESCIENCES LTD.: OPERATING SEGMENTS
- TABLE 129. ZYDUS LIFESCIENCES LTD.: PRODUCT PORTFOLIO
- TABLE 130. ZYDUS LIFESCIENCES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 131. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 132. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 133. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
- TABLE 134. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 135. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 136. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
- TABLE 137. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
- TABLE 138. AMNEAL PHARMACEUTICALS LLC: OPERATING SEGMENTS
- TABLE 139. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
- TABLE 140. AMNEAL PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET
- FIGURE 10. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET SEGMENTATION, BY DRUG CLASS
- FIGURE 11. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR CLOTRIMAZOLE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR NYSTATIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR FLUCONAZOLE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR KETOCONAZOLE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR TERBINAFINE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR TERCONAZOLE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
- FIGURE 19. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR ORAL, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR INTRAVENOUS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR TOPICAL, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 23. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 24. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 25. DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 30. COMPETITIVE DASHBOARD
- FIGURE 31. COMPETITIVE HEATMAP: DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET
- FIGURE 32. TOP PLAYER POSITIONING, 2023
- FIGURE 33. ASTELLAS PHARMA INC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 34. ASTELLAS PHARMA INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 35. ASTELLAS PHARMA INC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 36. MYCOVIA PHARMACEUTICALS, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 37. MYCOVIA PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 38. MYCOVIA PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 39. BAYER AG: NET SALES, 2021-2023 ($BILLION)
- FIGURE 40. BAYER AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 41. BAYER AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 42. BASILEA PHARMACEUTICA LTD: NET SALES, 2021-2023 ($BILLION)
- FIGURE 43. BASILEA PHARMACEUTICA LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 44. BASILEA PHARMACEUTICA LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 45. SCYNEXIS, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 46. SCYNEXIS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 47. SCYNEXIS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 48. GRUPO FERRER INTERNACIONAL S.A.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 49. GRUPO FERRER INTERNACIONAL S.A.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 50. GRUPO FERRER INTERNACIONAL S.A.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 51. PFIZER, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 52. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 53. PFIZER, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 54. ZYDUS LIFESCIENCES LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 55. ZYDUS LIFESCIENCES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 56. ZYDUS LIFESCIENCES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 57. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2021-2023 ($BILLION)
- FIGURE 58. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 59. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 60. AMNEAL PHARMACEUTICALS LLC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 61. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 62. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2023 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
